Antibodies Market Set for Exceptional Expansion, Aiming for US$ 834.2 Billion with a 13.4% CAGR by 2033

The antibodies market size is growing at a rapid pace due to the increasing use of monoclonal antibodies in research, medicines, and diagnostics. These incredibly adaptable and specialised compounds are now essential to the biotechnology and pharmaceutical industries. The market for antibodies is expected to increase steadily due to the increasing focus on targeted therapies and precision medicine. This presents a favourable prospect for businesses engaged in antibody production, research, and pharmaceuticals development.

From 2023 to 2033, the Antibodies Market is projected to grow at a CAGR of 13.4%, with a target market value of US$ 236.9 billion in 2023. The antibody market is projected to be worth US$ 834.2 billion by 2033. The absolute dollar growth of the global market, which amounts to US$ 597.3 billion, represents the total market value of the antibodies sector.

A renowned provider of market research and competitive data, Future Market Insights, predicts that by the end of 2031, the antibodies market will have grown by a factor of 21 and will be worth more than US$ 601.614 billion.

1. Hoffmann-La Roche Ltd., AbbVie Inc., Johnson & Johnson Services, Inc., Amgen Inc., and Bristol-Myers Squibb Company are among the market’s top competitors, according to FMI surveys. Three out of every four sales of antibodies worldwide are accounted for by these big players.

Get a Sample Copy of the Report:https://www.futuremarketinsights.com/reports/sample/rep-gb-1330

About 4% of the world’s population is afflicted by an autoimmune disease, according to reports from the National Stem Foundation (NSCF). Diabetes, MS, Crohn’s disease, and rheumatoid arthritis are the most prevalent autoimmune illnesses. The market for antibodies is predicted to be extremely in demand as a result of these chronic disorders.

Key Insights:

Antibodies are essential for treating medical conditions including autoimmune diseases, cancer, and several types of neurological diseases. Immunoglobulin (IG) is a type of antibody that is used for the prevention of lower respiratory tract infections and diseases caused by the vaccinia virus. Rising cases of viral infection will drive the demand for antibodies.

The prevalence of autoimmune diseases is on the rise, and they also have the potential to act as a host for multiple chronic ailments. Owing to these factors, the demand for antibodies is forecast to increase in upcoming years.

The COVID-19 pandemic boosted the demand for antibodies as patients suffering from COVID-19 were highly susceptible to contracting various other ailments and, in some cases, triggered autoimmune diseases in the patient.

Novel biosimilar antibody manufacturers are slashing their prices to compete with branded antibody manufacturers, especially in the European market. With the expiration of patents of renowned products, a boost in demand for biosimilar antibodies can be expected in upcoming years.

A reasonable hike in research and development activities among healthcare and pharmaceutical market leaders are working towards developing effective and economical antibodies and biosimilar antibodies, propelling growth in the market.

Parkinson’s and Sclerosis diseases are on the rise among older people which is a key factor fueling the demand for antibodies. There is an urgency to develop cheap and personalized medicines, novel and effective treatments, and advanced therapeutics in middle-income countries which is expected to positively influence the sales of antibodies.

The widespread application of antibodies in chronic disease treatment is accelerating which is predicted to create scope for market expansion in the near future.

Competitive Landscape:

Novartis AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi SA, Eli Lilly, and Co. are some of the key companies profiled in the full version of the report.

Future Market Insights (FMI) has found that market players are working towards developing new antibodies to treat cancer and other diseases. They are also researching to create long-acting antibody drugs to reduce healthcare costs.

In order to gain a competitive edge in the antibodies market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic mergers and acquisitions for portfolio expansion are in the cards as well.

More Insights into Antibodies Market

The United States is considered the dominant market in the North American region owing to modern healthcare infrastructural facilities and the presence of leading market players in the country. An increase in government funding and elevated purchasing power is expected to drive growth in the market.

The GCC countries led by Saudi Arabia are increasingly focusing on research and development on early diagnosis and screening of cancer to elevate the survival rate and chance of successful treatment. The contribution of antibodies is significant in this research. Hence, propelling growth in the market.

The development and production of antibodies are on a rise in China and are expected to surge significantly owing to increasing government investment in drugs and development coupled with growing awareness about various medical ailments like rheumatoid arthritis, cancer, and infections.

The Indian antibodies market is anticipated to grow at a rapid pace owing to rising cases of cancer and cardiovascular diseases along with the development of the healthcare system in the country. According to the reports of the Global Cancer Observatory, 1.322 million new cancer cases were registered in India in 2020, while 2.72 million people had cancer for 5 years. A surge in cancer patients will drive the demand for monoclonal antibodies for cancer treatment.

Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1330

Key Segments Covered in Antibodies Market Study

By Disease Indication

• Cardiovascular diseases
• CNS disorders
• Cancer
• Autoimmune Disorders

By Product Type

• Monoclonal antibodies
• Polyclonal antibodies
• Antibody-drug complexes (ADCs)

By End User

• Hospitals
• Long-term Care Facilities
• Research institutes

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube